Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pharmacological therapies and drug development targeting SARS-CoV-2 infection

Yizhou Jiang a, b, 1, Limor Rubin c, 1, Zhiwei Zhou a, Haibo Zhang d, Qiaozhu Su e, Sheng-Tao Hou b, f, Philip Lazarovici g, Wenhua Zheng a, **

a Centre of Reproduction, Development and Aging and Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Macau 999078, China
b Brain Research Centre and Department of Biology, School of Life Science, Southern University of Science and Technology, 1088 Xueyuan Blvd, Nanshan District, Shenzhen, Guangdong Province 518055, China
c Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 912001, Israel
d Anesthesia, Critical Care Medicine and Physiology, St. Michael’s Hospital, University of Toronto, Ontario, Canada
e Institute for Global Food Security, School of Biological Sciences, Queen’s University Belfast, Belfast BT9 5DL, United Kingdom
f Pharmacology, School of Pharmacy Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 912002, Israel
g Centre of Reproduction, Development and Aging and Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Macau 999078, China

** Correspondence to: Faculty of Health Sciences, University of Macau, Room 3057, Building E12, Avenida de Universidade, Taipa, Macau, China.

E-mail addresses: hou.st@sustech.edu.cn (S.-T. Hou), wenhuazheng@um.edu.mo (W. Zheng).

1 Equal contributions

https://doi.org/10.1016/j.cytogfr.2022.10.003
Received 27 July 2022; Received in revised form 7 October 2022; Accepted 7 October 2022
Available online 13 October 2022
1359-6101/© 2022 Published by Elsevier Ltd.

** ABSTRACT

The development of therapies for SARS-CoV-2 infection, based on virus biology and pathology, and of large- and small-scale randomized controlled trials, have brought forward several antiviral and immunomodulatory drugs targeting the disease severity. Casirivimab/Imdevimab monoclonal antibodies and convalescent plasma to prevent virus entry, Remdesivir, Molnupiravir, and Paxlovid nucleotide analogs to prevent viral replication, a variety of repurposed JAK-STAT signaling pathway inhibitors, corticosteroids, and recombinant agonists/antagonists of cytokine and interferons have been found to provide clinical benefits in terms of mortality and hospitalization. However, current treatment options face multiple clinical needs, and therefore, in this review, we provide an update on the challenges of the existing therapeutics and highlight drug development strategies for COVID-19 therapy, based on ongoing clinical trials, meta-analyses, and clinical case reports.

1. Introduction

The COVID-19 pandemic led to the mortality of millions of people worldwide and caused a major economic burden across the world. Coronaviruses are single-stranded RNA viruses that can infect a wide range of organisms [1] and have caused three massive outbreaks: (i) severe acute respiratory syndrome (SARS) caused by severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in 2003; (ii) Middle East respiratory syndrome (MERS) caused by Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012; (iii) COVID-19 caused by SARS-CoV-2 starting from 2019 [2].

SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA virus [3]. The size of the genome of SARS-CoV-2 is around 30 kb, comprising genes encoding spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, as well as other open reading frames regions encoding nonstructural proteins. SARS-CoV-2, like other coronaviruses, can infect animal cells because their S protein binds to angiotensin-converting enzyme 2 (ACE2) as the cellular receptor, and this virus-receptor interaction is a key factor that determines the range and susceptibility of their hosts [4,5]. After binding ACE2, SARS-CoV-2 enters the target cells via endocytosis machinery, resulting in the internalization and downregulation of ACE2 [6]. It is evident from different studies the occurrence of a multistep SARS-CoV-2 entry process [7] and that there is a large array of proteins apart from ACE2, which play crucial roles in the SARS-CoV-2 tropism, often in synergistic and complementary ways [8]. The COVID-19 viral tropism depends on the susceptibility and permissiveness of a specific host cell. During the epidemic, patients often presented with respiratory-like illnesses that progressed to severe pneumonia, suggesting that the lung is the primary tropism of SARS-CoV-2 [9].
The main symptoms upon infection with COVID-19 include fever, myalgia, cough, dyspnea, rhinorrhea, loss of smell/taste, sore throat, headaches, nausea/vomiting, diarrhea, and chest pain that may lead to multi-organ failure [10]. There are several potential treatment options for COVID-19 patients, including supportive care, respiratory support, antiviral treatment, therapeutic-specific antibodies, convalescent plasma and immunomodulatory agents including biological treatment. SARS-CoV-2 infection-induced over-activation of the immune system can lead to a cytokine storm in the host [2,11]. Even with the above treatments, acute respiratory distress syndrome (ARDS) caused by the cytokine storm is the major cause of mortality in critically ill patients [12,13]. Although a large number of anti-viral and immunomodulatory drugs have been proposed to target the key processes of viral infection and the advanced cytokine storm stage, only a few of them have shown significant, potent therapeutic efficacy and safety and are used in practice. Among the variety of COVID-19 clinical trials, the SOLIDARITY [14] and RECOVERY [15,16] trials were pivotal in therapy guidelines for the management of COVID-19 patients. The Infectious Disease Society of America (IDSA) and the USA National Institutes of Health (NIH) [17] and World Health Organization (WHO) [18] have produced comprehensive guidelines for the treatment and management of patients with COVID-19. In applying these treatment recommendations to patients with COVID-19 it is crucial to classify the patient’s disease severity, to target patients that will most benefit from the various drugs for COVID-19 and to minimize adverse events.

In this review, we summarize the current clinical and investigational therapeutic options for the management of patients with COVID-19 derived from the IDSA guidelines based on the patient’s current clinical stage of disease, emphasizing agents that have efficacy, demonstrated through well-designed randomized controlled clinical trials, and highlight future directions for developing novel pharmacological therapies as evident from ongoing different clinical trials and case reports. Albeit, vaccines appear to be safe and effective tools to prevent severe disease in those patients with risk factors who can progress to a more severe or critical disease and even death and hence, may benefit from pharmacotherapies. From a pharmacological mechanistic perspective, early during the infection, when SARS-CoV-2 viral load is high and the patient express mild or moderate symptoms, drug treatments targeting viral replication can be more effective since the adaptive immune system has not revealed yet an adequate response. Antiviral drugs (e.g., Remdesivir, Molnupiravir, Nirmatrelvir/Ritonavir) and neutralizing monoclonal antibody therapies (Table 1, Supplementary Material-Data in Brief), the earlier provided, the more efficacious they likely would be. There are subgroups of patients like immunocompromised patients, with high viral load even later in the disease process, who may still benefit from antiviral treatments, neutralizing monoclonal antibody therapies and convalescent plasma. Patients with severe COVID-19 are those who have pulmonary disease with hypoxia on room air needing treatment with low-flow oxygen. Most existing diagnostic criteria for severe COVID-19, consider an oxygen saturation level less than 93% and tachypnea (respiratory rate >30) (Fig. 1). This severity of critically ill patients requires more ventilator or oxygenation support, with either high-flow oxygen or noninvasive ventilation. High-flow oxygen therapy involves delivery of oxygen via special devices at rates up to 10–15 L/min. These patients are susceptible to a secondary infection phase with increase adaptive immune response. Azithromycin is a macrolide antimicrobial agent which acts against a broad range of gram-positive and gram-negative bacteria and plays an immunomodulatory role and has been widely used with and without ceftriaxone for the treatment of secondary infections in COVID-19 patients in moderate to severe phases, albeit its potential cardiotoxicity [33]. However, recent clinical studies indicate that the combination of Azithromycin and Hydroxychloroquine did not improve survival or length of hospitalization in patients with COVID-19 [34]. Therapeutic anticoagulation often employed in hospitalized patients resulted in a slight reduction in venous thromboembolism, but appears to have no effect on mortality in COVID-19 patients [35].

Glucocorticoids are potent anti-inflammatory drugs that mitigate the risk of ARDS in COVID-19 and other viral pneumonia, by inhibition of the development of cytokine storm and multi-organ damage. Glucocorticoids are recommended for use in the severe and critically ill patients in the hyper-inflammatory systemic phase, because they have shown the highest 28-day mortality benefit when used in these subpopulations. Dexamethasone 6 mg daily for 10 days is preferred, but doses up to 20 mg daily can also be applied [15]. Hydrocortisone 50 mg administered intravenously every 6 h is an alternative regimen [36].
Dexamethasone is known to suppress IL-1 signaling pathways, specifically c-Jun N-terminal kinase (JNK)-p38 kinase, leading to suppression of macrophage release of downstream cytokines, such as IL-6, IL-8, and TNF [108]. Similarly, Hydrocortisone use in patients with severe sepsis has been shown to significantly decrease IL-1β, interferon-γ (IFN-γ), TNF-α, and IL-6 levels [109]. Methylprednisolone has been reported to have some benefit in acute lung injury [110]. In addition, due to their immunosuppressive activity, glucocorticoids could also delay virus clearance in COVID-19 patients as they did in SARs and MERS patients [111]. In addition to glucocorticoids, IL-6 inhibitors (Tocilizumab, preferred over Sarilumab) or JAK inhibitors (Baricitinib, preferred over Tofacitinib) are recommended for those patients who present with elevated levels of inflammatory markers like C-reactive protein (CRP, Table 2 Supplementary Material-Data in Brief, Fig. 2). However, the clinical trials done so far, have not identified specific subpopulations of critically ill patients already being treated with corticosteroids that would benefit with additional treatment with IL-6 or JAK inhibitors. The IDSA guidelines recommend Dexamethasone, in critically ill patients with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Therefore, it is important to consider the use of these medications in the management of severe COVID-19 infection.

4. Antiviral selected drugs for COVID 19

SARS-CoV-2 infection is mediated by the binding of viral spike proteins (S-protein) to human cells through a two-step process, which involves angiotensin-converting enzyme-2 (ACE2) and angiotensin receptors (ATR) and hijacking the androgen-receptor regulated, transmembrane serine protease (TMPRSS) for viral entry due to its proteolytic cleavage of S-protein. The renin-angiotensin system (RAS) plays an important role in the development of ARDS. ACE2 is one of the enzymes involved in the RAS cascade. Virus S-protein binds to ACE2 to form a complex suitable for cellular endocytosis (Fig. 2). The down-regulation of ACE2 results in the excessive accumulation of angiotensin II, and it has been demonstrated that the stimulation of the angiotensin II type 1a receptor (AT1R) increases pulmonary vascular permeability, explaining the increased lung pathology when the activity of ACE2 is decreased. Upon endocytosis of the virus in the host cell, it replicates increasing the viral load. Antiviral drugs directed for the early infection and inflammatory phases of the COVID-19 disease (Fig. 1), target these essential steps of viral infection, including viral binding and attachment, anticoagulants (14%), vitamins (13%), immunomodulatory agents (13%), glucocorticoids (12%), analgesics/antipyretics (12%). Moreover, various combinations of those interventions were used, with up to seven different types of combinations [37].
endocytosis, and replication in the host cell [38]. As of June 2022, about 688 investigational anti-viral clinical trials have been registered to Clinicaltrial.gov and some selected main representatives according to the mechanism of action are presented in Table 1 (Supplementary Material-Data in Brief) and Fig. 2 and discussed below.

4.1. Pipeline and approved drugs targeting the SARS-CoV-2 virus spike protein and host cell recognition receptors

The monoclonal neutralizing antibodies, anti-spike protein S1 subunit-receptor binding domain, such as Casirivimab/Imdevimab, Bamlanivimab/Etesevimab, Sotrovimab and Bebtelovimab that block viral tropism, received FDA emergency use authorization for COVID-19 therapy (Table 1, Supplementary Material-Data in Brief). Among the various therapeutic and prophylactic strategies developed to contain the COVID-19 epidemic, immune-based SARS-CoV-2 elimination by passive immunization with COVID-19 polyclonal convalescent plasma transfusion has been also proven effective when administered in the early phase of the disease (within 72 h from symptom onset) and with a high titer (>1:160) of anti-SARS-CoV-2 neutralizing antibodies. This passive immunoglobulin therapy is one of the potential adjunctive therapies now being used for COVID-19 patients [39,40]. The rationale for such passive immunization is that plasma collected from patients after they recovered from COVID-19 might contain antibodies (IgG, IgA, IgM, IgE, and IgD) to SARS-CoV-2 and can be used to reduce the viremia and disease mortality in patients with life-threatening SARS-CoV-2 infections. However, larger clinical trials are required in order to further consolidate this therapy [41]. High-dose intravenous immunoglobulin (IVIG), based on clinical practical experience in autoimmune, inflammatory, and other infectious diseases, has been also been investigated, but the current evidence from the literature does not support the use of IVIG in COVID-19 patients [42].

Another preclinical therapeutic approach is based on strategies aimed at blocking ACE2 with monoclonal antibodies (Table 1, Supplementary Material-Data in Brief). Blockade of the ACE2 receptors could be also achieved through rationally designed small molecules [43], peptides [44], and exogenous administration of ACE2 [44]. The administration of a large amount of soluble form of ACE2 could represent an intriguing opportunity, since excessive ACE2 may competitively bind SARS-CoV-2 to neutralize or delay viral entry in the host cell and/or rescue ACE2 activity, which negatively regulates RAS and therefore, may confer a protective effect in lung injury. The safety and efficiency of recombinant human ACE2 were tested in a small cohort of healthy volunteers in phase 1 and in patients with ARDS in a phase 2 clinical study of COVID-19 patients [45]. However, the usage of ACE2 inhibitors to block the SARS-CoV-2 viral entry requires additional studies as there are conflicting findings and severe health complications reported for these inhibitors in COVID-19 patients. In preclinical research, in silico screening identified several novel compounds that can bind ACE2 or S-protein of SARS-CoV-2 and interfere with the interaction between this virus and its receptors [46]. In another study, compounds that can potentially inhibit the spike-ACE2 interaction were screened from 2701 FDA-approved drugs by using drug screening and in silico modeling. The findings indicated that the most potent effect of disrupting the S protein-ACE2 interaction was Thiostrepton, Oxytocin, Nilotinib, and Hydroxyacamptothecin [47], calling for repurposing them for COVID-19 by characterization of their efficacy in clinical trials. Besides the in silico studies, the efficacy of potential drugs that can block the interactions between the S protein and ACE2 was also supported by in vitro and animal studies. For example, Ceftazidime and Dalbavancin...
effectively prevented SARS-CoV-2 infection in Vero E6 cells [48,49], and Dalbavancin was active in mouse and rhesus macaque models [49]. However, although a large number of drugs have been identified by computational studies, clinical studies are required to confirm their safety and efficacy and ACE2-blocking monoclonal antibodies and inhibitors are not yet in clinical use.

Currently, available angiotensin receptor (ATR) antagonists such as Telmisartan, Eprosartan, Losartan and Valsartan are used as antihypertensive drugs in the clinic, by blocking the excessive angiotensin-mediated AT1R activation, and upregulation of ACE2 were considered for COVID-19 therapy (Table 1, Supplementary Material-Data in Brief). Albeit the controversy over the efficacy of ATR antagonists in the therapy of COVID-19 patients [50], they were found in clinical trials and case studies to reduce morbidity and mortality in hospitalized patients with pre-existing hypertension, by anti-inflammatory effects [51], but they are not yet in clinical practice.

Targeting of serine protease TMPRSS2 (Transmembrane Serine Protease-2) by either androgen blockade or direct inhibition is another approach in preclinical research and clinical trials for therapy of early SARS-CoV-2 infection. N-0385, a ketoconazole-based peptidomimetic provided a high level of protection and a therapeutic benefit after either single or multiple administrations in K18-hACE2 mice preclinical model of COVID-19 disease (Table 1, Supplementary Material-Data in Brief). Camostat mesylate is a TMPRSS2 inhibitor that has been shown to inhibit SARS-CoV-2 viral entry and hence viral replication [52]. Both Camostat and Nafamostat, approved drugs for the treatment of pancreatitis, are under clinical trials as potential repurposing drug candidates for COVID-19 therapy [53].

4.2. Chloroquine (CQ) and Hydroxychloroquine (HCQ): Drugs targeting virus endocytosis

The cell entry of SARS-CoV-2 is mediated by endocytosis, which is also a therapeutic target for the treatment of COVID-19. The most extensively studied drugs that target the virus endocytic pathway are chloroquine (CQ) and hydroxychloroquine (HCQ) [54] (Table 1, Supplementary Material-Data in Brief, Fig. 2). FDA gave emergency approval to CQ and HCQ in March 2020. It was reported that HCQ treatment effectively reduced the mortality of critical COVID-19 patients [55]. Although HCQ is considered to be safer than CQ, both drugs can cause severe or even lethal adverse effects [56]. Due to these adverse effects, on June 2020, these drugs were withdrawn by FDA for clinical applications.

4.3. Remdesivir and Molnupiravir: Targeting the RNA-dependent RNA polymerase (RdRp)

Remdesivir (GS-5734) is an adenosine analog that disrupts viral replication by inhibiting the RNA-dependent RNA polymerase (RdRp) [57] and acts as a terminator of RNA elongation. The clinical study showed that Remdesivir effectively shortened the recovery time and prevented the progression of respiratory disease in COVID-19 patients (Table 1, Supplementary Material-Data in Brief). Remdesivir became the first FDA-approved drug for treating COVID-19 [58]. The FDA issued an emergency-use authorization on May 2020, considering the benefits of the drug outweigh its risks in patients. Remdesivir is not recommended unless the potential benefit outweighs the potential risk in adults and pediatric patients (>28 days old) with an estimated glomerular filtration rate (eGFR less than 30 ml per minute) or in full-term neonates (>7 days and <28 days old) with serum creatinine ≥ 1 mg/dL. Possible side effects of Remdesivir include elevated liver function tests, an indication of inflammation or damage to the liver, and infusion-related reactions like low blood pressure, nausea, vomiting, sweating, and shivering. It is important to stress that besides its inhibitory effect on RdRp, recent evidence indicate that Remdesivir is blocking different steps of viral tropism. Remdesivir has a high affinity to the SARS-CoV-2 spike, ACE2, and TMPRSS2, proposing that it may also inhibit viral entry [59]. Remdesivir has a high affinity to the main proteases of SARS-CoV-2, suggesting that it may disrupt viral endocytosis and/or replication [60,61]. The effect was found to be more potent than that of Lopinavir (ABT-378), another widely used viral protease inhibitor [59]. In addition, Remdesivir may also affect viral assembly as it showed a high affinity to SARS-CoV-2 M protein and 3′-5′ exoribonuclease (nsp14) [59]. Remdesivir is not recommended for treating mild or moderate COVID-19 patients as it failed to show a significant therapeutic effect [62]. The final results of the WHO Solidarity randomized trial and updated meta-analyses indicate that Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. However, among other hospitalized patients, it presented a small positive effect against death and/or progression to ventilation [63]. Nevertheless, its efficacy in reducing mortality has not been clearly demonstrated. Molnupiravir, the first oral antiviral for COVID-19 is another safe RdRp inhibitor effective at reducing the risk of hospitalization and death in people with COVID-19, who are at increased risk of developing the severe disease (Table 1, Supplementary Material-Data in Brief). Molnupiravir has been authorized for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. Molnupiravir is effective mainly when used within 5-days of the onset of symptoms. A 5-days course seems to be safe without any obvious short-term side effects [64]. Additional drugs such as Favipiravir and Ribavirin target RdRp and Galidesivir targets the RNA polymerase, inhibiting viral RNA synthesis and evaluated in different clinical trials for COVID-19 [65].

4.4. Nirmatrelvir plus Ritonavir: targeting SARS-CoV-2 main protease in combination with a Cytochrome P450 inhibitor

Nirmatrelvir plus Ritonavir (Paxlovid™; Pfizer) is a co-packaging combination of Nirmatrelvir and Ritonavir tablets, intended for co-administration and developed for the treatment and post-exposure prophylaxis of COVID-19. Nirmatrelvir, is a potent peptidomimetic selective and reversible inhibitor of SARS-CoV-2 Mpro main protease (3C-like or nsp5 protease), while Ritonavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor and Cytochrome P450, family 3, subfamily A (CYP3A) inhibitor. As a result of this inhibition viral replication is prevented. Ritonavir acts as a pharmacokinetic enhancer, increasing the systemic exposure of Nirmatrelvir and decreasing its metabolism, and prolonging its half-life when the drugs are administered together. Nirmatrelvir plus Ritonavir received its first conditional authorization in December 2021 in the United Kingdom, for the treatment of COVID-19 in adults who do not require supplemental oxygen, and who are at increased risk for progression to severe COVID-19 [66]. January 2022, Nirmatrelvir plus Ritonavir (Paxlovid) received authorization in the EU for use in the same indication and is authorized by FDA for emergency use in the USA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (> 12 years of age and weighing ≥ 40 kg) at increased risk for progression to severe COVID-19. Treatment of symptomatic COVID-19 with Paxlovid resulted in a reduced risk of progression to severe COVID – 19 by 89% lower than the risk with a placebo, without evidence of severe safety concerns (Table 1, Supplementary Material-Data in Brief). Additional drug combinations such as Darunavir (protease inhibitor) and Cobicistat (pharmacokinetic enhancer) or Darunavir (protease inhibitor) is registered in clinical trials for COVID-19.

Other anti-viral drugs such as Clevudine, a synthetic pyrimidine analog that targets DNA polymerase and reverse-transcriptase enzyme, Oseltamivir, a neuraminidase inhibitor, and Umifenovir, a fusion inhibitor blocking the viral entry and replication, are being evaluated in investigational clinical trials for COVID-19. All these different approaches of anti-viral pharmacological therapy for COVID-19, early eliminate and inactivate the SARS-CoV-2 virus to prevent or limit the
immune dysregulation of the host and therefore the severity of the disease.

5. Immunotherapy selected drugs for COVID-19

From the very beginning of the COVID-19 pandemic, it became clear that dysregulation of immune responses against SARS-CoV-2 is one of the main features of disease pathogenesis, especially in patients with severe disease, and studies aimed at rebalancing the immune response by different modulators initiated early on. SARS-CoV-2 infection-induced hyper-inflammation (cytokine storm) is a major cause of death [2,67]. In addition to the anti-viral therapies, immunotherapies that broadly or specifically target the immune response have been approved or are considered in different investigational clinical trials for COVID-19 [68], Table 2 (Supplementary Material-Data in Brief) and Fig. 2 present approved and selected investigational clinical trials on immunotherapy based on glucocorticoids, pan-immune suppressors of inflammation, protein tyrosine-kinase inhibitors of the JAK-STAT signaling pathway, anti-IL-1, 6 and GM-CSF cytokines and interferons, stimulators of anti-viral defense.

5.1. Glucocorticoids

A variety of glucocorticoids, including Dexamethasone, Hydrocortisone, Methylprednisolone, etc., have been evaluated in clinical trials (Table 1, Supplementary Material-Data in Brief). The largest study, conducted by the RECOVERY collaborative group, resulted in the regulatory approval of Dexamethasone as the standard of care for patients with SARS-CoV-2 requiring oxygen therapy. Dexamethasone and Methylprednisolone are effective in reducing the severity of COVID-19 and associated comorbidities such as chronic obstructive pulmonary diseases [69]. Although acute glucocorticoid treatment is still considered to be the best therapy for severe COVID-19, chronic glucocorticoid treatment could cause the occurrence of a variety of adverse diseases such as arteriosclerosis, hypertension, diabetes, etc. Albeit glucocorticoid treatment is essential for critically ill patients experiencing ARDS [70], glucocorticoid drugs represent a double-edged sword in COVID-19 therapy [71,72]. Attention should be given to their profound adverse effects, especially for those with comorbid conditions [73].

5.2. JAK-STAT signaling pathway inhibitors

The JAK-signal transducer and activator of transcription (JAK-STAT) signaling pathway mediates extracellular interleukins and interferons signal by membrane receptor activation and is a key inflammatory pathway that regulates the production of pro-inflammatory cytokines [74,75]. Over-activation of the JAK-STAT pathway could lead to a cytokine storm in critically ill patients [76]. JAK inhibitors have been clinically used for the treatment of several inflammatory and autoimmune diseases, [77,78]. For this reason, JAK inhibitors have been repurposed as pharmacological therapies for COVID-19 (Table 2, Supplementary Material-Data in Brief). The STOP-COVID clinical trial investigated the efficacy of the JAK inhibitor Tofacitinib, in 289 hospitalized patients with mild to moderate disease. Patients were randomized to receive oral Tofacitinib 10 mg twice a day, for 14 days, versus a placebo. At day 28, the composite outcome of death or respiratory failure was lower in the Tofacitinib group compared to the placebo. Beginning of 2020, it was predicted by studies of artificial intelligence that the JAK inhibitor Baricitinib could potentially inhibit cell entry and of SARS-CoV-2 [79]. This hypothesis was subsequently further supported by mechanistic studies [80]. In a meta-analysis study of eleven reports on the safety and efficacy of JAK-inhibitors Ruxolitinib and Baricitinib in COVID-19 patients, it was found that Baricitinib therapy caused a lower risk of death [81]. In COV-BARRIER, ACTT-2, and other clinical trials, systemic Baricitinib treatment revealed quite confidently that it decreased all-cause mortality in hospitalized individuals with moderate to severe COVID-19. Moderate-certainty evidence indicated that systemic JAK inhibitors probably decreased the risk of worsening clinical status and make little or no difference in the rate of adverse events of any grade, whilst they probably decrease the occurrence of serious adverse events (Table 2, Supplementary Material-Data in Brief). Because of its potent anti-inflammatory properties, Baricitinib was recommended by WHO for the treatment of patients with severe or critical COVID-19 on January 2022 [82]. Imatinib, another JAK inhibitor was tested in COUNTER-COVID and INVENT-COVID clinical trials and conferred clinical benefits in hospitalized patients with COVID-19, but further studies are required to validate these findings. Given the key role of the JAK-STAT pathway in immune responses, the use of JAK inhibitors may result in broad adverse effects. For example, the use of Baricitinib may delay viral clearance and increase the risk of secondary infections such as the herpes virus, due to its immunosuppressive activity and carries the risk of increased thromboembolic events [83]. Many lines of evidence suggest that SARS-CoV-2 infection may result in the down-regulation of JAK signaling in certain cell lines, and inhibition of JAK may promote viral infection [84]. In addition, a recent study showed that patients who have previously received treatment of JAK inhibitors Baricitinib, Tofacitinib, and Upadacitinib may show diminished responsiveness to COVID-19 vaccination [85]. Among the studied cases with different ages and different drug pre-treatments, older patients or patients treated with Upadacitinib tend to have higher non-response rates [85]. Although this aspect still requires further investigation, it raises an important concern that the use of immunosuppressive drugs may weaken the protection by vaccination. In summary, oral treatment with 4 mg/day up to 14 days of JAK inhibitors is effective in preventing SARS-CoV-2 progression and has the potential to decrease mortality in patients requiring low-flow oxygen but not in those with severe symptoms. JAK inhibitors are in general used in hospitals concomitantly with systemic delivered glucocorticoids.

5.3. Anti-cytokine therapy

To find safe and effective drugs to mitigate the cytokine storm, repurpose of the interleukin (IL) – 1 blockade agents is one of the safest ways to stop this innate immune response and may offer an important therapeutic option in the hyper-inflammatory phase of COVID-19 [86]. Therefore, drugs that block the IL-1 receptor, such as Anakinra, or drugs that block IL-1 signaling, such as Canakinumab, can potentially interrupt the vicious hyper-inflammatory loop. These drugs have been investigated in clinical trials as potential therapies for COVID-19 (Table 2, Supplementary Material-Data in Brief). Anakinra is a recombinant human IL-1 receptor antagonist. It is approved by the FDA to treat rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. It is used “off-label” to treat severe chimeric antigen receptor T cell-mediated cytokine release syndrome and macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis. Canakinumab is a human monoclonal antibody that targets the β-subunit of IL-1 and is approved by the FDA for the treatment of systemic juvenile idiopathic arthritis and Still’s disease. In the SAVE and SAVE-MORE trials, hospitalized patients who had moderate or severe COVID-19 pneumonia and plasma-soluble urokinase plasminogen activator receptor (suPAR) levels ≥ 6 ng/mL were randomized to receive either Anakinra or placebo. The studies found that patients who received Anakinra had a lower risk of clinical progression of COVID-19, compared to those who received a placebo. CORIMUNO-ANA-1, a randomized controlled trial that compared the use of Anakinra to usual care in 116 hospitalized patients who were hypoxic but did not require high-flow oxygen or ventilation, did not improve outcomes in patients with mild-to-moderate COVID-19 pneumonia [87]. Administration of Anakinra may be beneficial for treating severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis (sHLH), but larger clinical studies are required to validate this concept [88]. After reviewing the results of the clinical trials and taking into consideration the fact that...
Cytokine and Growth Factor Reviews 68 (2022) 13–24

Y. Jiang et al.

suPAR assays are not widely available to guide the use of Anakinra, FDA concluded that there is insufficient evidence to recommend either for or against the use of Anakinra for the treatment of COVID-19 in hospitalized patients.

CANCID, a randomized controlled trial that evaluated Canakinumab in hospitalized patients with COVID-19 who were hypoxicemic but did not require ventilator support, reported that the use of Canakinumab did not improve the likelihood of survival without invasive mechanical ventilation. Because of these results, FDA does not recommend Canakinumab for the treatment of COVID-19, except in a clinical trial (BIIa) (Table 2, Supplementary Material-Data in Brief).

IL-6 is a key cytokine in the pathogenesis of severe to critical SARS-CoV-2 infection and excessive IL-6 levels may lead to an imbalance in innate and adaptive immunity [89]. Therefore, IL-6 antagonism has an important role in the management of severe and critical phases of COVID-19. Sarilumab and Tocilizumab are human monoclonal antibodies binding and antagonizing soluble as well as membrane-bound interleukin-6 receptors, hindering IL-6 from exerting its pro-inflammatory effects. Multiple studies have examined the therapeutic efficacy of a single dose of 400 mg of Tocilizumab (8 mg/kg), or Sarilumab at 400 mg, delivered intravenously, in hospitalized patients with SARS-CoV-2, resulting in variable findings due to the administration of the drug at different stages of the disease process and variable severity of the disease. In CORIMUNO, REMAP-CAP, RECOVERY, and other clinical trials, Tocilizumab improved survival and other clinical outcomes in hospitalized COVID-19 patients with hypoxia and systemic inflammation. These benefits were seen regardless of the amount of respiratory support and were added to the benefits of systemic corticosteroids. Tocilizumab reduced all-cause mortality in all studies and reduced mechanical ventilation and length of stay in randomized controlled trials in hospitalized COVID-19 patients. Based on these findings it received approval from EMA FDA on June 2021 for therapy of COVID-19 (Table 2, Supplementary Material-Data in Brief). In REMAP-CAP, SARICOR, PROSPERO, Sarilumab improved outcomes, including survival in critically ill patients with COVID-19 receiving organ support in intensive care units. Meta-analysis of clinical trials of patients hospitalized for COVID-19 indicated that administration of IL-6 antagonists, compared with usual care or a placebo, was associated with survival in critically ill patients with COVID-19 pneumonia and excessive IL-6 levels may lead to an imbalance in systemic corticosteroids. Tocilizumab reduced all-cause mortality in all studies and reduced mechanical ventilation and length of stay in randomized controlled trials in hospitalized COVID-19 patients. Based on these findings it received approval from EMA FDA on June 2021 for therapy of COVID-19 (Table 2, Supplementary Material-Data in Brief). In REMAP-CAP, SARICOR, PROSPERO, Sarilumab improved outcomes, including survival in critically ill patients with COVID-19 receiving organ support in intensive care units. Meta-analysis of clinical trials of patients hospitalized for COVID-19 indicated that administration of IL-6 antagonists, compared with usual care or a placebo, was associated with survival in critically ill patients with COVID-19 pneumonia and excessive IL-6 levels may lead to an imbalance in systemic corticosteroids. Tocilizumab reduced all-cause mortality in all studies and reduced mechanical ventilation and length of stay in randomized controlled trials in hospitalized COVID-19 patients. Based on these findings it received approval from EMA FDA on June 2021 for therapy of COVID-19 (Table 2, Supplementary Material-Data in Brief).

5.4. Stimulation of antiviral defense by Interferons

Interferons are divided into type I (IFN-α and IFN-β), type II (IFN-γ), and type III (IFN-λ) and have a fundamental role in the innate immune system, being part of the first line of defense against viral infections. Differential induction of type I and III interferon genes in the upper respiratory tract of patients with COVID-19 were reported [94]. Therapy in clinical trials with recombinant super-compound interferon was associated with a shorter time of clinical improvement than IFN-α in the treatment of moderate-to-severe COVID-19 when combined with baseline antiviral agents. Treatment with IFN-α2b significantly reduced the duration of detectable virus in the upper respiratory tract and parallel reduced the duration of elevated blood levels for the inflammatory markers, and the average days of hospitalization were found lower (Table 2, Supplementary Material-Data in Brief). Early intervention with IFN-α, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes [95]. Emerging data suggest that IFN-1-mediated boosting of patients’ immunity, achieved directly through the exogenous administration of IFN-β early post- viral infection, might play a therapeutic role against SARS-CoV-2 [96]. In SG016, UW-20-074, and other clinical trials, IFN-β does not appear to provide an increased survival benefit in hospitalized patients with COVID-19 but may help reduce the risk of intensive care admission. The addition of interferon-β to the standard of care resulted in a significant reduction in time to clinical improvement but no significant benefit in terms of reduction in mortality and length of hospital stay in moderate-to-severe cases of COVID-19 [97]. In several clinical case studies, a positive effect of IFN-β was noted on the rate of clinical stabilization and recovery of patients with community-acquired pneumonia and viral infections. IFN-γ may be considered potential booster-adjvant immunotherapy in a subset of immunocompromised COVID-19 patients, and concomitant IFNγ therapy may support antibiotic strategies. Presently, according to the COVID-19 treatment guidelines, based on the results from the call for additional clinical trials since the GM-CSF blockade strategy may have broad immunomodulatory effects given that it could affect the secretion of multiple pro-inflammatory cytokines and chemokines by myeloid cells. The GM-CSF-based therapies are worthwhile to be further pursued but in the design of the clinical trials care should be taken concerning dose, delivery route, timing of administration, and disease severity for each therapeutic approach [90].

Tumor necrosis factor α (TNFs), one of the pro-inflammatory cytokines commonly upregulated in acute lung injury, triggers cytokine storm and facilitates SARS-CoV-2 interaction with ACE2. TNF-α inhibitors, therefore, may serve as an effective therapeutic strategy for attenuating disease progression in severe SARS-CoV-2 infection [91]. These TNFs blocking agents have long been used in the clinical setting to treat inflammatory and autoimmune diseases and therefore, TNFα blockade can be achieved by monoclonal antibodies (such as Infliximab, Adalimumab, etc.), fusion proteins (Etanercept) and dominant negative proteins (INRI03). Indeed several clinical trials are ongoing in patients with rheumatoid arthritis and intestinal bowel disorders with pulmonary complications due to COVID-19 infection. From the preliminary results, it appears that therapy with TNF-α inhibitors is associated with a lower probability of hospitalization and severe COVID-19 when compared to other treatments for an underlying inflammatory disease [92]. Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells that markedly improved the cytokine and chemokine storm and restored the impaired mitochondrial and glycolytic function in white blood cells leading to increased survival [93]. Definitely, cytokine-targeted therapy for COVID-19 represents an investigational attractive pharmacological approach that may further succeed by enrolling stratified patients based on the establishment of defined biomarkers for different phases of the disease.
present clinical trials, and concerning the lack of thorough evidence on the occurrence of adverse effects, the FDA recommends against the administration of interferons (α, β, and λ) in hospitalized and non-hospitalized patients, unless in the setting of a clinical trial.

6. Resistance to current pharmacological therapies in new SARS-CoV-2 variants

Since the beginning of the SARS-CoV-2 outbreak, the virus has been continuously adapting to its hosts and efforts have been made to continuously map its genome and to identify possible mutations that may offer the virus a selective advantage. The newly emerged strains can rapidly become the dominant variant all over the world due to their higher transmissibility and enhanced replication in human airway epithelial cells [97]. For example, the S01Y.V1 (B.1.1.7), S01Y.V2 (B.1.351) and the P.1 variants carry an N501Y mutation in the RBD of the spike protein that increases their binding affinity to ACE2 receptor, potentiating the virus transmission [98,99]. The S01Y.V2 and P.1 variants have two additional mutations in the spike protein (E484K and K417N/F) that may not only further enhance binding affinity but also help the virus escape recognition affecting their neutralization by antibodies [99,100]. The nearest emerged variant, Omicron, has 37 mutations on the spike gene, endowing it with much higher infectivity [101]. These changes indicate their ability to evade immunity generated in response to a previous infection or vaccination. Moreover, mutations on viral proteins that serve as key drug targets may lead to the loss of potency of current anti-viral therapies. It was reported that both monoclonal antibodies and convalescent sera showed low or no neutralizing activity against the Omicron variant. [102]. A Pfizer booster dose could successfully elicit neutralization activity against the omicron variant, though the neutralization efficiency is much lower than that against the D614G and Delta variants [102]. A recent study tested the efficiency of several monoclonal antibodies and antiviral drugs on the omicron variant as well as a number of other earlier variants. Among the tested monoclonal antibodies, Casirivimab, Tixagevimab, Gilgavimab, and Sotrovimab showed remarkably reduced neutralizing activity against the Omicron variant, characterized by much higher FRNT50 values [103]. Strikingly, the Omicron variant was almost completely resistant to neutralization by Etesevimab, Bamlanivimab, and Imdevimab. Cochrane COVID-19 study register reviewed the randomized controlled trials that evaluated SARS-CoV-2-neutralizing monoclonal antibodies, including fragments, alone or combined, versus an active comparator, placebo, or no intervention, for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) of COVID-19 [104]. For PrEP, there is a decrease in the development of clinical COVID-19 symptoms (high certainty), infection with SARS-CoV-2 (moderate certainty), and admission to the hospital (low certainty) with Tixagevimab/Gilgavimab. There is low certainty of a decrease in infection with SARS-CoV-2, and development of clinical COVID-19 symptoms, and a higher rate for all-grade adverse effects with Casirivimab/Imdevimab. The Omicron variant also carries mutations on RdRp and the main protease of SARS-CoV-2, indicating that it may escape from current antiviral treatments [105]. To test this possibility, Takashita et al. tested Remdesivir, Molnupiravir, and PF-07304814 on the Omicron variant and found that in vitro the inhibitory concentration of 50% values of these three compounds against the Omicron variant were similar to those against the early strains, indicating that they may still be effective [106]. However, the effectiveness has not yet been verified by clinical studies. Also, the current anti-viral therapies are still at risk of losing potency as the viruses are continuously mutating.

7. Prospective of drug development against COVID-19

COVID-19 has already resulted in millions of deaths worldwide, and it is essential to develop efficient therapies as quickly as possible. Rapid progress has been made to understand the precise machinery of viral infection and immune responses. The SARS-CoV-2 infection leads to dysregulation of immune pathways. Therapies focusing on suppressing cytokine activity demonstrate some success in clinical trials and case reports. Current evidence supports the use of Dexamethasone in hospitalized patients requiring oxygen. Early use of IL-6 inhibitors is beneficial in hypoxemic patients and CRP level can serve to identify patients who may benefit from IL-6 inhibitors. JAK inhibition in combination with glucocorticoids is emerging as a potential therapeutic option for patients with moderate to severe symptoms. However, antiviral therapy is not effective in hospitalized patients with severe symptoms. The clinical data on Anakinra, hyperimmune immunoglobulin/convalescent plasma are yet limited and inconclusive. Although more mechanistic studies are still needed to identify potential therapeutic targets, developing new drugs based on existing knowledge should be a promising solution at the current stage. Conventional methods include structure-based drug design, which is a highly validated method that has been previously used in developing anti-viral drugs against HIV-1 and MERS-CoV [106,107]. Artificial intelligence-based drug design is a newly emerged approach that has been recently used to discover novel drugs based on machine and deep and reinforcement learning algorithms [108,109]. Combining these drug design approaches with virtual drug screening and high-throughput screening approaches could greatly aid in the process of developing novel lead compounds for COVID-19 therapy [110]. Nevertheless, developing a new drug could take years, and quicker approaches must be taken to combat this devastating pandemic. Repurposing pre-existing drugs is a quick solution to this developing demand, as their dosage, safety, and mechanism of action are already well established. Drug repurposing against COVID-19 has been successful by using cell-based or computational screening. For example, Remdesivir is a repurposed anti-viral drug and has become an FDA-approved drug for treating COVID-19 [111]. However, most of the drug repurposing is still at the computational level, lacking experimental validation and requiring investigational clinical trials [112]. As the lethal cytokine storm may occur in advanced-stage COVID-19 patients, early detection of viral infection, the establishment of valid clinical biomarkers, and treatment with anti-viral drugs are essential. However, anti-viral therapies are at risk of losing potency because the targeted viral proteins are continuously mutating. A combination of anti-viral therapies with a different mechanism of action is a solution to the possible occurrence of strains resistant to the certain anti-viral drugs. In addition, developing broad-spectrum antiviral drugs is crucial for not only controlling the ongoing COVID-19 pandemic but also the possible outbreak of new viruses in the future. Immunotherapy in COVID-19 needs to be further progressed by clinical trials to establish solid knowledge and clinical experience and to determine the optimal patient-directed strategy based on validated biomarkers of the different phases of disease severity. The development of immunotherapies approaches must take into consideration the immune heterogeneity of clinically-similar COVID-19 patients and their incorporation in the clinic will help both in therapy decisions as well for application in other severe viral infections.

Funding

This research was supported by National Natural Science Foundation of China (32070969), The Science and Technology Development Fund, Macau SAR (File No. 0127/2019/A3, 0113/2018/A3 and 0038/2020/ AMJ), The Guangdong Provincial Funding Committee for Medical and Applied Fundamental Research (2022-Natural Science Foundation), the University of Macau (File No. MRY2G2018-00134-FHS and MRY2G2020-00158-FHS). PL holds the Jacob Gitlin Chair in Physiology and is affiliated and supported by David R. Bloom Center for Pharmacy, Dr. Adolf and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics, and the Grass Center for Drug Design and Synthesis of Novel Therapeutics at the Hebrew University of Jerusalem, Israel.
CRediT authorship contribution statement

L.R. and Y.J.Y. wrote the manuscript. Z.Z., R.L., S.H., P.L., H.Z., Q. S. and W.Z. reviewed and revised the manuscript. All authors read and approved the final manuscript.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.cytogfr.2022.10.003.

References

[1] S. Perlman, J. Netland, Coronaviruses post-SARS: update on replication and pathogenesis, Nat. Rev. Microbiol. 7 (6) (2009) 439–450.

[2] Y. Jiang, L. Rubin, T. Peng, L. Liu, X. Xing, P. Lazarovici, W. Zheng, Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy, Int. J. Biol. Sci. 18 (2) (2022) 459–472.

[3] Y. Finkel, O. Mizrahi, A. Nachshon, S. Weingarten-Gabbay, D. Morgenstern, bradykinin 2 receptors, Life Sci. 293 (2022), 120284.

[4] W. Li, M.J. Moore, N. Vasilella, J. Sui, S.K. Wong, Cytokine gene expression in cells of NK type and bradylkinin 2 receptors, Life Sci. 293 (2022), 120284.

[5] H. Hofmann, K. Pyrc, L. van der Hoek, M. Geier, B. Berkhout, S. Pohlmann, transforming growth factor-β1 is a functional receptor for the SARS coronavirus, Nature 492 (6656) (2002) 450–454.

[6] A.E. Portales, E.R. Mustafa, C.I. McCarthy, M.P. Cornejo, P.M. Couto, M. Miron, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature 492 (6656) (2002) 450–454.

[7] Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to 2019-nCoV infection in Wuhan, China, J. Med. Virol. 98 (2020) 1045–1050, e9.

[8] Y. Jiang, L. Rubin, T. Peng, L. Liu, X. Xing, P. Lazarovici, W. Zheng, Cytokine storm in COVID-19 disease, Cytokine Growth Factor Rev. 54 (2020) 62–69.

[9] D. Wang, B. Hu, C. Fu, Z. Liu, M. Jiang, B. Wang, X. Xiang, Z. Cheng, Y. Xiong, Y. Zhao, L. Yi, W. Zheng, W. Peng, Clinical characteristics of 138 hospitalised patients with COVID-19 pneumonia in Wuhan in China: a descriptive study, Lancet 395 (10223) (2020) 507–513.

[10] Y.O. Puntmann, M.L. Carej, I. Wieters, M. Fahim, A. Hoffmann, S. Shchendyryn, F. Escher, M. Vasa-Nicotera, A.M. Zeiber, M. Velthuis, E. Engel, Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), JAMA Cardiol. 5 (11) (2020) 1265–1273.

[11] D. Singh, E. Singh, A reassessment of the neurological aspects in COVID-19 infection, J. Chem. Neuroanat. 122 (2022), 102101.

[12] E. Tacconelli, K.A.O. Tikkinen, S. Trelle, H. Zaid, J.A. Rottingen, S. Swaminathan, S. McGinty, M.T. Medina, M.L. Mesa Rubio, M.C. Miranda-Montoya, J. Nel, E. Lopardo, P. Lydon, N. Magrini, T. Maguire, S. Manevska, O. Manuel, C. Cappel-Porter, N. Cerrato, T.S. Chow, N. Como, J. Eustace, P.J. Garcia, F. Ader, A.M. Al-Bader, A. Alhasawi, E. Allum, A. Alotaibi, C.A. Alvarez-Moreno, P. Kieny, R. Malekzadeh, S. Murthy, K.S. Reddy, M. Roses Periago, P. Abi Hanna, V. Sathiyamoorthy, Q. Abdool Karim, M.M. Alejandria, C. Hernandez Garcia, M. Rodriguez, SARS-CoV-2 infection: the role of cytokines in COVID-19 disease, Lancet 395 (10223) (2020) 497–506.

[13] V.O. Puntmann, M.L. Carej, I. Wieters, M. Fahim, A. Hoffmann, S. Shchendyryn, F. Escher, M. Vasa-Nicotera, A.M. Zeiber, M. Velthuis, E. Engel, Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), JAMA Cardiol. 5 (11) (2020) 1265–1273.

[14] B. Kuhar, J. Nehira, A. Malhotra, S.O. Kotchoni, The race for COVID-19 vaccines: the various types and their strengths and weaknesses, J. Pharm. Pract. (2022), 89719002197248.

[15] D. Wang, B. Hu, C. Fu, Z. Liu, M. Jiang, B. Wang, X. Xiang, Z. Cheng, Y. Xiong, Y. Zhao, L. Yi, W. Zheng, W. Peng, Clinical characteristics of 138 hospitalised patients with COVID-19 pneumonia in Wuhan in China, JAMA Cardiol. 5 (11) (2020) 1265–1273.

[16] B. Kuhar, J. Nehira, A. Malhotra, S.O. Kotchoni, The race for COVID-19 vaccines: the various types and their strengths and weaknesses, J. Pharm. Pract. (2022), 89719002197248.

[17] NIH, COVID-19 Treatment Guidelines. (2022) https://www.nih.gov/.nih/news/.
Y. Jiang et al.

Cytokine and Growth Factor Reviews 68 (2022) 13–24

22

T. Strom, M. Cronhjort, R.R. Wahlin, S.M. Jakob, L. Cioccari, B. Venkatesh, N. Hammond, V. Jha, S.N. Myatra, M.Q. Jensen, J. Leistner, V. Jha, S.N. Myatra, M.Q. Jensen, J. Schwab, E.C. Madsen, C. Gluud, T. Lange, A. Perner, Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial, Acta Anaesthesiol. Scand. 65 (10) (2021) 1421–1430.

J.D. Zhu, W. Meng, X.J. Wang, H.C. Wang, Broad-spectrum antiviral agents, Front Pharmacol. 11 (2020), CD013600.

P. Richardson, I. Griffin, C. Tucker, D. Smith, O. Oechsle, A. Phelan, M. Rawling, P. Ciechanowicz, A. Rakowska, M. Sikora, L. Rudnicka, JAK-inhibitors in COVID-19: a living systematic review, Cochrane Database Syst. Rev. 5 (2022) 1953.

R.R. Deshpande, A.P. Tiwari, N. Nyayanit, M. Modak, In silico molecular docking study of renin-angiotensin system, J. Med. Res. Methodol. 22 (1) (2021) 173.

F. Coperchini, L. Chiovato, G. Ricci, L. Croce, F. Magri, Motroni, The cytokine storm in COVID-19: further advances in our understanding of the role of cytokines involved, Cytokine Growth Factor Rev. 58 (2021) 82–91.

L.Z.F. Gross, M. Sacerdoti, A. Piiper, S. Zeuzem, A.E. Leroux, R.M. Biondi, ACE2 in the era of SARS-CoV-2: controversies and novel perspectives, Front Mol. Microbiol 6 (2015) 517.

P. Cummins, K. Rawat, Pipeline pharmacological therapies in clinical trial for COVID-19 Pandemic: a recent update, Curr. Pharm. Rep. 6 (5) (2020) 228–240.

B.G. Bertha, J.D. Folts, Phasic mitral blood flow and regional left ventricular dimensions: possible mechanism of active assist to ventricular filling, Circulation 83 (1991) 901–911.

A. F. Wease, A.A. Alhosary, A.S. Abdel-Moneim, Molecular docking reveals invermectin and remdesivir as potential repurposed drugs against SARS-CoV-2, Front Microbiol 11 (2020), 592908.

A.K. Singh, A. Singh, R. Singh, A. Miera, An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19, Diabetes Metab. Syndr. 16 (2) (2022), 102396.

B. Young, T.T. Tan, Y.S. Leo, The place for remdesivir in COVID-19 treatment, Lancet Infect. Dis. 21 (1) (2021) 20–21.

W.H.O.S.T. Consortium, Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses, Lancet 399 (10339) (2022) 1941–1953.

A.K. Singh, A. Singh, R. Singh, A. Miera, An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19, Diabetes Metab. Syndr. 16 (2) (2022), 102396.

F. Coperchini, L. Chiovato, G. Ricci, L. Croce, F. Magri, Motroni, The cytokine storm in COVID-19: further advances in our understanding of the role of cytokines involved, Cytokine Growth Factor Rev. 58 (2021) 82–91.

S. Slutsky, J.M. Penninger, Human recombinant soluble ACE2 in severe COVID-19, Crit. Care 25 (1) (2021), 108723.

J.D. Ravid, O. Leiva, V.C. Chitalia, Janus kinase signaling pathway and its role in inflammatory diseases, Front Immunol. 11 (2020) 1664.

S. Jamilloux, T. El Jammal, L. Vuitton, M. Gerfaud-Valentin, S. Kerever, P. Seve, L. Xu, Y.C. Li, P.M. Kamau, L. Yang, H.Q. Liu, J.W. Xu, J.K. Chen, Y.T. Zheng, X. Wang, Y. Li, J. Wang, L. Zou, G. Wang, M.L. Yang, Z.L. Duan, F.L. Liu, L. Jin, C.B. Long, M. Zhang, X.P. Tang, J. Liu, J. Yin, C. Wang, X. Song, X. Li, M. Miao, Effects of renin-angiotensin system blocking spike protein-ACE2 interaction, Signal Transduct. Target Ther. 6 (1) (2021) 198.

R.R. Deshpande, A.P. Tiwari, N. Nyayanit, M. Modak, In silico molecular docking study of renin-angiotensin system, J. Med. Res. Methodol. 22 (1) (2021) 173.

T. Strom, M. Cronhjort, R.R. Wahlin, S.M. Jakob, L. Cioccari, B. Venkatesh, N. Hammond, V. Jha, S.N. Myatra, M.Q. Jensen, J. Leistner, V. Jha, S.N. Myatra, M.Q. Jensen, J. Schwab, E.C. Madsen, C. Gluud, T. Lange, A. Perner, Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial, Acta Anaesthesiol. Scand. 65 (10) (2021) 1421–1430.

J.D. Zhu, W. Meng, X.J. Wang, H.C. Wang, Broad-spectrum antiviral agents, Front Pharmacol. 11 (2020), CD013600.

P. Richardson, I. Griffin, C. Tucker, D. Smith, O. Oechsle, A. Phelan, M. Rawling, P. Ciechanowicz, A. Rakowska, M. Sikora, L. Rudnicka, JAK-inhibitors in COVID-19: a living systematic review, Cochrane Database Syst. Rev. 5 (2022) 1953.

R.R. Deshpande, A.P. Tiwari, N. Nyayanit, M. Modak, In silico molecular docking study of renin-angiotensin system, J. Med. Res. Methodol. 22 (1) (2021) 173.
Dr. Qiaozhu Su is an Associate Professor in the School of Biological Sciences at Queen’s University Belfast in the United Kingdom. She leads a research team to decipher the molecular mechanisms linking redox signalling (e.g., CREBH/ERK) with metabolic syndrome and the parasympathetic nervous system in lipid metabolism and insulin resistance. Dr. Su’s research program has been supported by funding from NIH and USDA in the USA, BHF and NICHS in the UK.

Lazarovici Philip. Obtained his Ph.D. degree in pharmacology and toxicology 1980 from The Hebrew University, post graduated 1984 on neurobiology at the Weizmann Institute of Science, Israel and was a visiting scientist from 1984 to 1988 in the Section of Growth Factors at the National Institutes of Child Health and Human Development, NIH, Bethesda, USA. He was a Fogarty visiting scientist at NIH (1990–1998), Drexel University (2004–2011) and Temple University (2012–2015), Philadelphia, USA. Present position: Professor Emeritus, Jacob Gitlin Chair in Physiology, School of Pharmacy, The Hebrew University of Jerusalem, Israel. Main research fields: neuronal and non-neuronal pharmacological activities of nerve growth factor, trkA, p75NTR and α9β1-integrin signaling and role in neuroprotection, angiogenesis and tumor development; toxins, lead compounds, drug discovery and development, cell therapy, stem cells, neurological disorders.

Wenhua Zheng is a professor at University of Macau, Faculty of Health Sciences. Main research fields: neuropharmacology; aging, neuronal degenerative disorders including Alzheimer’s disease and degenerative retinal diseases; molecular mechanisms of neuronal cell death; drug development.